Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Update

Evaxion Biotech A/S (NASDAQ:EVAX) was the target of a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 58,600 shares, a drop of 52.9% from the January 31st total of 124,500 shares. Approximately 5.5% of the company’s shares are sold short. Based on an average trading volume of 2,240,000 shares, the days-to-cover ratio is presently 0.0 days.

Hedge Funds Weigh In On Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Catalina Capital Group LLC purchased a new stake in Evaxion Biotech A/S (NASDAQ:EVAX) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned 2.98% of Evaxion Biotech A/S at the end of the most recent quarter. 11.04% of the stock is owned by institutional investors.

Evaxion Biotech A/S Stock Down 2.6 %

NASDAQ EVAX traded down $0.05 during trading on Monday, reaching $1.89. 125,281 shares of the company’s stock traded hands, compared to its average volume of 3,551,884. The company’s 50 day simple moving average is $3.35 and its two-hundred day simple moving average is $9.08. Evaxion Biotech A/S has a 12-month low of $1.78 and a 12-month high of $22.05. The firm has a market cap of $2.22 million, a price-to-earnings ratio of -1.30 and a beta of -0.28. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80.

Analyst Ratings Changes

Several analysts have recently weighed in on EVAX shares. Lake Street Capital decreased their price target on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th. HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of Evaxion Biotech A/S in a report on Thursday, February 20th.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.